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for cortical masses over a decade ago. However, the rise of 
small renal masses discovered incidentally on imaging and 
advancements in systemic agents against particular renal 
cell carcinoma (RCC) subtypes have led to a resurgence of 
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Abstract 
Pathologic characteristics of extirpated renal cell carcinoma (RCC) specimens <7  cm were reviewed to get better information on technical 
nuances of renal mass biopsy (RMB). Specimens were stratified according to tumor stage, nuclear grade, size, histology, presence of lymphovas-
cular invasion (LVI), necrosis, and sarcomatoid features. When considering pT1 (0–7 cm) tumors, pT1b (4–7 cm) RCC masses were more likely 
to have necrosis (43% vs 16%, P < 0.001), LVI (6% vs 2%, P = 0.024), high-grade nuclear elements (29% vs 17%, P < 0.001), and sarcomatoid 
features (2% vs 0%, P = 0.006) compared with pT1a (0–4 cm) tumors. Additionally, pT3a tumors were more highly associated with necrosis 
(P = 0.005), LVI, sarcomatoid features, and high-grade disease (P for all < 0.001) when compared to pT1 masses. For masses ≤ 4 cm, pT3a can-
cers were more likely to demonstrate necrosis (38% vs 16%, P < 0.001), LVI (22% vs 2%, P < 0.001), high-grade nuclear elements (45% vs 17%, 
P < 0.001), and sarcomatoid features (12% vs 0%, P < 0.001) compared to pT1a tumors. Similarly, for masses 4–7 cm, pathologic T3a tumors 
were significantly more likely to have sarcomatoid features (12% vs 2%, P = 0.006) and LVI (22% vs 6%, P = 0.003) compared to pT1b tumors. 
In summary, pT3a tumors and those RCC masses >4 cm exhibit considerable histologic heterogeneity and may harbor elements that are not 
easily appreciated with limited renal sampling. Therefore, if  RMB is considered for renal masses greater than 4 cm or those that abut sinus fat, a 
multi-quadrant biopsy approach is necessary to ensure adequate sampling and characterization of the mass.
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Concerns regarding insufficient diagnostic yield coupled with 
false positive and negative rates contributed to the initial low 
utilization of renal mass biopsy (RMB) as a diagnostic tool 
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and pathologic stage (pT1a, pT1b, and pT3a). Within these 
groups, the annotation was made regarding histologic ele-
ments including nuclear grade and presence of LVI, necrosis, 
and sarcomatoid features (7). Low- and high-grade nuclear 
elements were defined as Fuhrman grades 1–2 and 3–4, 
respectively. 
The data were analyzed using R software, version 9. The 
categorical variables were compared using Chi square test 
with Bonferroni correction to determine significance at a 
level of P < 0.05. 
Results
A total of 659 RCC specimens met the inclusion criteria. 
The pathologic characteristics of our cohort are included in 
Table 1. In summary, the mean tumor size was 3.5 cm (range, 
0.9–7.0 cm). Pathologic distribution of tumors included 404 
(61%) pT1a, 169 (26%) pT1b, and 86 (13%) pT3a. Histologic 
subtypes were distributed as 74% clear cell, 19% papillary, 
6% chromophobe, and 1% other. Specimen stratification 
revealed 66% of tumors 0–4 cm and 34% of tumors 4–7 cm 
with no statistical difference in histologic subtype distribu-
tion across renal tumor sizes. Low and high nuclear grades 
were recorded in 486 (74%) and 156 (24%) cases, respectively. 
Necrosis, LVI, and sarcomatoid features occurred in 26, 6, 
and 2% of cases, respectively.
interest in incorporating RMB into the diagnostic algorithm 
of renal tumors (1). Furthermore, there has been growing 
interest in the use of genetic and molecular assessments that 
can potentially improve our ability to determine renal tumor 
biology and clinical behavior through RMB (2). Addition-
ally, the increased adoption for active surveillance across a 
spectrum of RCC masses renewed optimism in the value of 
RMB information (3). 
Current American Urological Association (AUA) clinical 
principles state that RMB should be considered when a mass 
is suspected to be hematologic, metastatic, inflammatory, or 
infectious. In the setting of a solid renal mass, AUA expert 
opinion does not recommend RMB for young or healthy 
patients who are willing to accept uncertainties associated 
with RMB, or for older or frail patients who will be managed 
conservatively regardless (4). Conversely, the European Uro-
logical Association practice guidelines recommend the use of 
RMB in patients who are candidates for active surveillance 
of small masses, to obtain histology before ablative treat-
ments, and to select the most suitable medical and surgical 
treatment strategy in the setting of metastatic disease (level 
3 evidence) (5). 
The ideal RMB would not only differentiate between 
benign and malignant tumors, but importantly characterize 
key histologic features of RCC tumors to better guide the use 
of conservative versus interventional strategies. RMB is over-
all a safe procedure with core biopsy having superior accu-
racy compared to final needle aspiration (FNA) (6). There is 
some variability, however, in diagnostic accuracy particularly 
with respect to the impact of intratumoral heterogeneity on 
the interpretation of pathologic outcomes (6). Therefore, we 
evaluated the incidence of histologic heterogeneity, necrosis, 
lymphovascular invasion (LVI), and sarcomatoid features, in 
extirpated RCC specimens to better guide specific nuances of 
the RMB technique to optimize interpretation and accuracy.
Patients and Methods
After institutional review board (IRB) approval, the records 
of patients who underwent surgical resection of renal masses 
at a single academic institution between January 2000 and 
August 2017 were reviewed. Patients having incomplete 
data and benign masses were excluded. Masses >7 cm were 
excluded due to the likelihood of extirpation versus diag-
nostic biopsy in general clinical practice. The baseline demo-
graphic, disease, and treatment-related parameters were 
extracted from the records in a de-identified manner. These 
data included age, gender, race, body mass index (BMI), 
American Society of Anesthesiologists (ASA) score, Eastern 
Cooperative Oncology Group (ECOG) performance status, 
and type of surgery (radical versus partial nephrectomy). 
Final pathology reports of RCC specimens were used to 
stratify the masses according to size (0–4  cm and 4–7  cm) 
Table 1: Pathologic characteristics of 659 RCC tumors ≤ 
7cm in size


























Lymphovascular Invasion 38 (6)
Sarcomatoid features 14 (2)
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masses 4–7cm, pathologic pT3a tumors were significantly 
more likely to have sarcomatoid features (12% vs 2%, P = 
0.006) and LVI (22% vs 6%, P < 0.001) compared to pT1b 
tumors (Table 4). 
Discussion
Renal mass biopsy is a tool increasingly available for accu-
rate characterization of renal pathology prior to definitive 
intervention. While histologic heterogeneity of RCC is rec-
ognized, a quantitative assessment is more limited. Here, we 
investigated the pathologic characteristics of 659 extirpated 
RCC specimens to better characterize various elements that 
may impact the disease biology. In this regard, we observed 
When considering pathologic T1 tumors, pT1b lesions 
(4–7  cm in size) were more likely to have necrosis (43% vs 
16%, P  <  0.001), LVI (6% vs 2%, P  =  0.024), high-grade 
nuclear elements (29% vs 17%, P  <  0.001), and sarcoma-
toid features (2% vs 0%, P = 0.006) when compared to pT1a 
tumors (0–4 cm in size) (Table 2).
Pathologic pT3a tumors were more highly associated 
with necrosis (P=0.005), LVI, sarcomatoid features, and 
high-grade disease (P for all <0.001) when compared to pT1 
masses (Table 3). Specifically, in masses <4 cm, pT3a can-
cers were more likely to demonstrate necrosis (38% vs 16%, 
P < 0.001), LVI (22% vs 2%, P < 0.001), high-grade nuclear 
elements (45% vs 17%, P  < 0.001), and sarcomatoid fea-
tures (12% vs 0%, P < 0.001) compared to pT1a tumors. For 
Table 2: Pathologic characteristics of 573 pT1 tumors stratified by size (0–4cm vs. 4–7cm)


























Necrosis 66 (16) 72 (43) <0.001
LVI 9 (2) 10 (6) 0.024
Sarcomatoid features 0 (0) 4 (2) 0.006
Table 3: Pathologic characteristics of 659 RCC tumors < 7cm in size stratified by stage (pT1 vs. pT3a)


























Necrosis 138 (24) 33 (38) 0.005
LVI 19 (3) 19 (22) <0.001
Sarcomatoid features 4 (1) 10 (12) <0.001
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RCC masses >4 cm and pT3a lesions, irrespective of size, 
were more likely to harbor areas of necrosis, LVI, high-grade 
nuclear elements, and sarcomatoid features. 
Several other investigators have similarly investigated 
histologic characteristics of kidney cancers. Bedke et al.  (8) 
demonstrated LVI in 5.5% of subjects with RCC and showed 
an association with advanced TNM (tumor, lymph node, 
metastasis) stages, high Fuhrman grade, and sarcoma-
toid features. LVI was the strongest factor associated with 
metastatic spread in all patients and also in a subgroup of 
patients with clear cell RCC. Pichler et al. (9) reported that 
sarcomatoid features, a highly aggressive form of RCC, were 
present in 5–8% of clear-cell RCC, 8–9% of chromophobe 
RCC, and 2–3% of papillary RCC. Additionally, about 75% 
of patients with sarcomatoid RCC presented with metastatic 
disease. Khor and colleagues (10) noted that tumor necrosis 
was present in 21% of cases of resected renal masses. After 
adjusting for age, tumor stage, and tumor size, necrosis was a 
significant predictor of overall survival on the multivariable 
analysis. 
Nuclear grade heterogeneity is known to occur in small 
renal masses. In particular, Ball and colleagues (7) observed 
Fuhrman grade heterogeneity in 81.3% of all RCC tumors 
and 93.8% of high-grade specimens. Additionally, they inves-
tigated discordance within RCC specimens, defined as the 
highest grade is present in less than 50% of the specimen. 
They found discordance among 31.3% of all RCC tumors 
and 25% of high-grade specimens. A small-scale study con-
firmed that there is a statistically significant difference in the 
proportion of high-grade cases when compared with conven-
tional (36%) and total (60%) samplings (11).
Qualitative data comparing histologic heterogeneity based 
on size and stage were limited in our literature review. Zhang 
et al. (12) showed a significant correlation between tumor 
size with grade and stage of lesions. Specifically, larger 
tumors were prone to have a higher grade and stage, and 
the probability of being clear cell subtype grew higher as 
the tumor size increased. In a recent study of a multi-quad-
rant biopsy technique for large renal masses (T2 or greater), 
25.0% revealed multiple grades of tumors present among the 
cores, including 14.1% that contained high- and low-grade 
tumors. Of the 13 patients with sarcomatoid features identi-
fied from multi-quadrant biopsies, only 30.8% had sarcoma-
toid features present in every core sampled (13).
Heterogeneity is well established in RCC at the chromo-
somal and genomic sequence level. Moch et al. demonstrated 
variable intratumor loss of Von Hippel-Lindau (VHL) and 
chromosome 3 polysomy by fluorescence in situ hybridiza-
tion in 53 patients with pT2 or greater RCC. However, the 
cytogenetic variability seen in these cases did not correlate 
with grade or stage (2, 14). Likewise, using multiregional 
exome sequencing, Gerlinger et al. (15) demonstrated intra-
tumor heterogeneity in somatic mutations and genomic 
copy number across multiple regions in primary tumors and 
metastatic lesions in patients with clear cell RCC. Further 
research continues to identify genetic mutations with a recent 
meta-analysis tallying more than 19 (16). 
Given the intratumoral heterogeneity demonstrated in 
this study, the probability of  identifying all pathological fea-
tures increases with each area tested by reducing sampling 
error. Hobbs et al. (17) demonstrated in an ex vivo study that 
obtaining multiple renal mass biopsy cores, compared with 
a single core biopsy, considerably improved diagnostic yield 
for histologic subtyping, accuracy, and cancer identification. 
Second peripheral and second central cores both increased 
cancer identification versus a single peripheral core (56– 77% 
and 80%, respectively). They found no difference in cancer 
identification based on the location of a single core (central 
Table 4: Pathologic characteristics of 659 RCC tumors ≤ 7cm in size stratified by stage (pT1 vs. pT1b vs. pT3a)

































Necrosis 66 (16) 72 (43) 33 (38) <0.001
LVI 9 (2) 10 (6) 19 (22) <0.001
Sarcomatoid features 0 (0) 4 (2) 10 (12) <0.001
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vs peripheral). These findings were reinforced by Abel et 
al. (13) in a prospective, in vivo study of multi-quadrant 
biopsies of  large renal masses (T2 or greater). The use of  at 
least four versus three or fewer biopsies from separate, solid 
enhancing areas of  tumor decreased nondiagnostic rate (11 
to 0%) and improved sensitivity for detecting sarcomatoid 
features (25 to 87%) without increasing the rate of  com-
plications. Multicenter studies are needed to confirm these 
findings.
There are limitations to this study. It is retrospective in 
nature and examines prior pathology reports. As such, we 
only have reports of the highest Fuhrman grade of an entire 
extirpated mass. Additionally, our institution currently fol-
lows the International Society of Urological Pathology 2018 
guidelines requiring one section for each centimeter of the 
largest diameter of the tumor, with special attention to the 
areas with different macroscopic aspects including necrosis, 
but no precise guidelines for the distribution of sampling. 
The problem is that many RCC that appear homogeneous 
to the naked eye are heterogeneous under the microscope. 
Necrosis and sarcomatoid transformation can be discov-
ered sometimes on a meticulous and skilled analysis by the 
naked eye, but tumor grade and eosinophilic cell change can-
not  (18). This point makes current routine tumor sampling 
an inconsistent sampling method (19, 20).
Furthermore, there are no standard recommendations on 
how renal carcinomas should be graded in needle-core biop-
sies. At our institution, we assign the highest grade to total 
specimen, but a system similar to Gleason scoring could 
prove more useful for stage stratification and treatment deci-
sions. Further research is necessary to incorporate RMB into 
a standard diagnostic protocol for patients with renal corti-
cal tumors.
Conclusion
Renal cell carcinoma masses >4 cm and pT3a tumors (irre-
spective of size) exhibit considerable histologic heterogeneity 
and may harbor elements that are not easily appreciated with 
limited renal sampling. Therefore, if  by cross-sectional radi-
ography, renal masses appearing larger than 4  cm or those 
abutting sinus fat, a single percutaneous biopsy sample is 
likely not adequate. A multi-quadrant biopsy is necessary 
for these tumors to ensure accurate capture of histologic ele-
ments that may better reflect the differing underlying biology 
of these tumors. The minimum number and specific location 
of biopsies require continued investigation. 
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